A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE SRL
Via Sette Santi, 1 50131 - Firenze (Firenze) Phone +39 055 56801 Fax +39 055 582771
Via Sette Santi, 1 50131 - Firenze (Firenze) Telefono +39 055 56801 Fax +39 055 582771
Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.
Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.
MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.
Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.
What does it really make Menarini unique? The diversity and authenticity of our key resource - the People. Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.
Menarini employees make all the difference, every day.
Ogni giorno mettiamo in pratica i nostri valori. 4 valori, che hanno dato vita a Menarini e ne hanno forgiato la storia.
Menarini investe continuamente nella scienza e nelle tecnologie all'avanguardia per lo sviluppo di una pipeline di nuovi prodotti che facciano la differenza nella vita dei pazienti affetti da gravi patologie.
Menarini è un’azienda privata completamente integrata con una lunga storia di collaborazioni di successo in tutto il Mondo. In Menarini abbiamo una conoscenza ed esperienza consolidata frutto della nostra capacità di Ricerca & Sviluppo nelle aree terapeutiche chiave, accompagnate da un’eccellente presenza capillare in tutto il Mondo.
Il nostro Team dedicato di Business Development è impegnato a valutare ed esplorare nuove opportunità innovative.
Dalla distribuzione di pasti e medicinali, dai kit per andare a scuola alla promozione dello sport all'aiuto per le donne in gravidanza: essere responsabili, per noi di Menarini, significa tradurre le buone intenzioni in sforzi concreti. Aiutando gli altri diamo il nostro contributo a migliorare il mondo che ci circonda, a partire da noi.
Che cosa rende davvero Menarini unica? La diversità ed autenticità del nostro valore più importante - le Persone. La nostra diversità culturale ci aiuta a guidare l'innovazione, ad adattarci ai cambiamenti di mercato, ad affrontare le sfide, ad ispirare idee e a promuovere la nostra crescita.
Chi lavora in Menarini fa la differenza, ogni giorno.
Multiple myeloma is the second most common hematologic malignancy in adult patients1.
The incidence of multiple myeloma has increased since 19902. According to the World Health Organization, in 2020, there were approximately 51,000 new cases and 32,000 deaths from this cancer in Europe3. It is more common in older people with a median age of diagnosis at around 70 years4.
Multiple myeloma develops from a type of white blood cells in the bone marrow. These cells are called plasma cells and they grow in an abnormal fashion yielding in too many of the same type of these cells in the patient’s bone marrow5. Clinically, this can cause renal impairment, hypercalcemia, lytic bony lesions, and anemia.2
While the treatment of multiple myeloma has improved over the last 20 years, and overall survival has increased considerably, the disease remains incurable6, and nearly all patients will eventually relapse and develop disease that is refractory to all approved anti-myeloma therapies.
Therefore, there continues to be a high unmet medical need for new therapies, particularly those with novel mechanisms of action that can overcome resistance to current anticancer drugs.7
We at the Menarini Group are dedicated to improving outcomes for patients with multiple myeloma. Our actions reflect our commitment to making a difference to patients’ lives and optimizing patient care at all stages: through non-invasive blood testing and developing new treatment options.
References
1 Heider M, Nickel K, Högner M, Bassermann F. Oncol Res Treat. 2021;44(12):672-681.
2 Cowan AJ, et al. JAMA Oncol. 2018; 4(9):1221–1227
3 World Health Organization. 2020. Available at:
https://gco.iarc.fr/today/data/factsheets/cancers/35-Multiple-myeloma-fact-sheet.pdf
4 Blimark CH, et al. Haematologica. 2018: 103 (3): 506-513
5 Cancer Research UK. Available at:
https://www.cancerresearchuk.org/about-cancer/myeloma/about
6 International Myeloma Foundation. Available at:
https://www.myeloma.org/multiple-myeloma/multiple-myeloma-diagnosis
7 Dhanasiri S, et al. Clin Ther.2021;43(11):1983–1996
Discover our stories from all over the world
Menarini � un�azienda privata completamente integrata con una lunga storia di collaborazioni di successo in tutto il Mondo. In Menarini abbiamo una conoscenza ed esperienza consolidata frutto della nostra capacità di Ricerca & Sviluppo nelle aree terapeutiche chiave, accompagnate da un�eccellente presenza capillare in tutto il Mondo.
Il nostro Team dedicato di Business Development � impegnato a valutare ed esplorare nuove opportunità innovative.
Scopri le nostre storie da tutto il mondo